BR112019001808A2 - composição farmacêutica anticâncer - Google Patents
composição farmacêutica anticâncerInfo
- Publication number
- BR112019001808A2 BR112019001808A2 BR112019001808-5A BR112019001808A BR112019001808A2 BR 112019001808 A2 BR112019001808 A2 BR 112019001808A2 BR 112019001808 A BR112019001808 A BR 112019001808A BR 112019001808 A2 BR112019001808 A2 BR 112019001808A2
- Authority
- BR
- Brazil
- Prior art keywords
- present
- pharmaceutical composition
- salt
- compound
- provides
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 abstract 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 abstract 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente invenção provê uma composição farmacêutica para o tratamento ou a prevenção do câncer, contendo, como um ingrediente ativo, um composto possuindo uma estrutura química específica e uma atividade de inibição da formação de um complexo c-myc/max/dna ou um sal farmaceuticamente aceitável do mesmo. a presente invenção proporciona a utilização médica da composição farmacêutica, de acordo com a presente invenção, para tratar ou prevenir o câncer. a presente invenção também provê um método para tratar ou prevenir o câncer, compreendendo a administração, para um sujeito com necessidade de tratamento, de uma quantidade eficaz do composto, do seu sal ou da composição, de acordo com a presente invenção, contendo o composto e seu sal.
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160097435 | 2016-07-29 | ||
| KR10-2016-0097435 | 2016-07-29 | ||
| KR10-2016-0159904 | 2016-11-29 | ||
| KR10-2016-0159889 | 2016-11-29 | ||
| KR20160159898 | 2016-11-29 | ||
| KR10-2016-0159885 | 2016-11-29 | ||
| KR10-2016-0159898 | 2016-11-29 | ||
| KR10-2016-0159887 | 2016-11-29 | ||
| KR20160159900 | 2016-11-29 | ||
| KR20160159887 | 2016-11-29 | ||
| KR20160159904 | 2016-11-29 | ||
| KR20160159885 | 2016-11-29 | ||
| KR10-2016-0159900 | 2016-11-29 | ||
| KR20160159889 | 2016-11-29 | ||
| KR10-2017-0094694 | 2017-07-26 | ||
| KR1020170094694A KR101920163B1 (ko) | 2016-07-29 | 2017-07-26 | 항암용 약학 조성물 |
| PCT/KR2017/008106 WO2018021849A1 (ko) | 2016-07-29 | 2017-07-27 | 항암용 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019001808A2 true BR112019001808A2 (pt) | 2019-05-07 |
Family
ID=61204134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019001808-5A BR112019001808A2 (pt) | 2016-07-29 | 2017-07-27 | composição farmacêutica anticâncer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11464770B2 (pt) |
| EP (1) | EP3492082B1 (pt) |
| JP (1) | JP6691635B2 (pt) |
| KR (1) | KR101920163B1 (pt) |
| CN (1) | CN109715159B (pt) |
| AU (1) | AU2017304546B2 (pt) |
| BR (1) | BR112019001808A2 (pt) |
| CA (1) | CA3032293C (pt) |
| FI (1) | FI3492082T3 (pt) |
| MX (1) | MX2019001210A (pt) |
| RU (1) | RU2724340C1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102532517B1 (ko) * | 2021-02-05 | 2023-05-15 | 한국화학연구원 | 신규한 설폰아미드 화합물 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약제학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3012684B2 (ja) | 1989-12-08 | 2000-02-28 | 大日本製薬株式会社 | チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩 |
| KR100574351B1 (ko) * | 2004-05-18 | 2006-04-27 | 한국화학연구원 | 4-퀴놀린온 유도체를 포함하는 농원예용 살균제 조성물 |
| KR100916160B1 (ko) | 2007-02-21 | 2009-09-08 | (주)바이오버드 | 약제학적 항암 조성물 |
| EP2124948B1 (en) | 2007-02-21 | 2017-07-26 | NC bit, Inc. | Compositions for treating hyperproliferative vascular disorders and cancers |
| KR101074212B1 (ko) | 2009-05-18 | 2011-10-14 | 한국화학연구원 | 4－퀴놀린온 유도체 화합물을 포함하는 수목용 살충제 조성물 및 이를 이용한 살충방법 |
| KR101335458B1 (ko) * | 2011-01-04 | 2013-12-10 | 한국화학연구원 | 백혈병 치료용 약학조성물 |
| EP2878677A1 (en) | 2013-11-28 | 2015-06-03 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Activators of protein phosphatase 5 |
-
2017
- 2017-07-26 KR KR1020170094694A patent/KR101920163B1/ko active IP Right Grant
- 2017-07-27 RU RU2019105506A patent/RU2724340C1/ru active
- 2017-07-27 AU AU2017304546A patent/AU2017304546B2/en active Active
- 2017-07-27 US US16/321,631 patent/US11464770B2/en active Active
- 2017-07-27 EP EP17834790.2A patent/EP3492082B1/en active Active
- 2017-07-27 JP JP2019503984A patent/JP6691635B2/ja active Active
- 2017-07-27 CA CA3032293A patent/CA3032293C/en active Active
- 2017-07-27 CN CN201780047159.0A patent/CN109715159B/zh active Active
- 2017-07-27 BR BR112019001808-5A patent/BR112019001808A2/pt active Search and Examination
- 2017-07-27 FI FIEP17834790.2T patent/FI3492082T3/fi active
- 2017-07-27 MX MX2019001210A patent/MX2019001210A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6691635B2 (ja) | 2020-04-28 |
| US11464770B2 (en) | 2022-10-11 |
| EP3492082A4 (en) | 2020-03-11 |
| EP3492082A1 (en) | 2019-06-05 |
| RU2724340C1 (ru) | 2020-06-23 |
| MX2019001210A (es) | 2019-09-04 |
| FI3492082T3 (fi) | 2023-04-20 |
| EP3492082B1 (en) | 2023-03-15 |
| CA3032293C (en) | 2021-09-07 |
| CA3032293A1 (en) | 2018-02-01 |
| KR20180013755A (ko) | 2018-02-07 |
| US20210315879A1 (en) | 2021-10-14 |
| JP2019525930A (ja) | 2019-09-12 |
| AU2017304546A1 (en) | 2019-02-28 |
| KR101920163B1 (ko) | 2018-11-19 |
| CN109715159A (zh) | 2019-05-03 |
| CN109715159B (zh) | 2022-04-12 |
| AU2017304546B2 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| BR112018012765A2 (pt) | composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico. | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
| WO2015035410A8 (en) | Cancer therapy | |
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| BR112019001808A2 (pt) | composição farmacêutica anticâncer | |
| BR112021000183A8 (pt) | Preparação medicinal para uso externo | |
| BR112019005217A2 (pt) | terapia combinada | |
| BR112018067663A2 (pt) | compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos | |
| BR112017002805A2 (pt) | Composição para prevenção ou tratamento de obesidade contendo ácido alfa-lipóico e n- acetilcisteína como ingredientes ativos | |
| BR112022002692A2 (pt) | Agentes antimaláricos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |